stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Return on assets
Genmab A/S Sponsored ADR's return on assets over the twelve months to 30 June 2026 was 8.30%, down 1.7 percentage points from fiscal 2025 (9.99%). Over the past ten years it has ranged from 9.99% (fiscal 2025) to 47.9% (fiscal 2017) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 9.99% | (9.65) |
| FY2024 | 19.6% | 6.21 |
| FY2023 | 13.4% | (5.63) |
| FY2022 | 19.1% | 5.69 |
| FY2021 | 13.4% | (13.09) |
| FY2020 | 26.5% | 8.47 |
| FY2019 | 18.0% | (4.40) |
| FY2018 | 22.4% | (25.47) |
| FY2017 | 47.9% | 29.22 |
| FY2016 | 18.6% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 10.5% |
| GMAB Genmab A/S Sponsored ADR | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR compare | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| RVMD Revolution Medicines, Inc. compare | −57.1% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement